Search company, investor...

BioSystem Development

Founded Year



Acquired | Acquired

Total Raised


About BioSystem Development

BioSystem Development produces the disposable AssayMAP, a micro chromatography cartridges which reduces development time, increases efficiency and enables high-throughput solutions for bioprocess, biomarker and life science applications.In December 2011, BioSystem Development was acquired by Agilent Technologies. The valuation of BioSystem Development was undisclosed. Other terms of the deal were not released.

Headquarters Location

802 Deming Way Suite 172

Madison, Wisconsin, 53717,

United States


Missing: BioSystem Development's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioSystem Development's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

BioSystem Development Patents

BioSystem Development has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Biotechnology, Proteins, Life sciences industry, Biochemistry methods


Application Date


Grant Date



Related Topics

Molecular biology, Biotechnology, Proteins, Life sciences industry, Biochemistry methods



BioSystem Development Frequently Asked Questions (FAQ)

  • When was BioSystem Development founded?

    BioSystem Development was founded in 2002.

  • Where is BioSystem Development's headquarters?

    BioSystem Development's headquarters is located at 802 Deming Way, Madison.

  • What is BioSystem Development's latest funding round?

    BioSystem Development's latest funding round is Acquired.

  • How much did BioSystem Development raise?

    BioSystem Development raised a total of $3.98M.

  • Who are the investors of BioSystem Development?

    Investors of BioSystem Development include Agilent Technologies, Madison Development Corporate Venture Debt Fund, Marshfield Investment Partners, Silicon Pastures, Chippewa Valley Angel Investors Network and 5 more.

  • Who are BioSystem Development's competitors?

    Competitors of BioSystem Development include Sirion Biotech, Scienion, HTG Molecular Diagnostics, Amnis Corporation, WaferGen Bio-systems and 13 more.

Compare BioSystem Development to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Everist Health Logo
Everist Health

Everist Health (formerly Everist Genomics and Genetics Squared) is a personalized medicine company which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies. Through their tools, the company seeks to help physicians improve medical outcomes and reduce the total cost of care. EGI's products integrate with mobile digital services, smartphones, and tablet computers resulting in advanced medical technology.

Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.


PrognostiX is a Cleveland, Ohio based company involved in the development of molecular biomarkers that aid in the diagnosis and treatment of cardiovascular disease. The company has developed the CardioMPO Test; which is an enzyme immunoassay used to evaluate patients that are at risk for major adverse cardiac events.


Proteoplex is a spinout of Incyte Genomics and aims to provide the scientific community with key functional genomic and proteomic tools and services in the areas of Gene Expression, Protein Expression and Cell-Based Assays. The proteomics product addresses a major barrier in defining the function of proteins in cells; how to quickly and cheaply test thousands of samples for the presence of a particular set of proteins. This protein product will be closely followed by the launch of gene expression products to solve a similar barrier in the genomics market; how to quickly and cheaply interrogate thousands of samples against a defined set of important genes.


SIRS-Lab with its diagnostic portfolio! VYOO Sepsis Test is a multiplex pcr detection kit to identifiy bacteria and fungi in whole blood! LOOXSTER sample preparation kit concentrates bacterial and fungal DNA! With expert knowledge in molecular diagnostic, critical care medicine, microbiology, assay design and gene expression service!

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.